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disease-related information, e.g. epidemiology, frequency of
interventions (Federal Health Monitoring, German Foundation
Organ Transplantation, German Index for Stem Cell Transplan-
tation, Literature). RESULTS: Bavarian demand for blood prod-
ucts of approximately 2,850 units per workday (750,000 units
per year) was estimated. Potential blood donators add up to
approximately 8,474 million people. Assuming a donation rate
of 3% an approx. number of 250,000 donators exist. Most
active segment of donators is between 32–56 years. It will be
affected by the demographic shift, means a declining population
of approximatelt 425,000 people in this segment. Stem cell trans-
plantations (+50% in the last 7 years) and organ transplantations
(+15% in 2005) lead to an increasing demand of blood products.
Statistical data show an increasing life expectancy of 5 years until
2050 (male 81.1/female 86.6 years) entailing higher cancer inci-
dence rates (+50% until 2050) affecting blood consumption
(20% of all blood products are used in cancer therapies). The
German blood market volume for the year 2005 is estimated to
be €500 mill. For the Bavarian sub-segment a value of €75
million can be deducted. CONCLUSION: Further research and
survey will be necessary to derive strategic recommendations for
the blood market participants. Then a dynamic population
model will be developed to project future effects on blood
demand and supply.
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OBJECTIVES: Health Intervention and Technology Assessment
program (HITAP), a newly established Health Technology
Assessment (HTA) agency in Thailand, has tried to develop the
systematic, transparent, and participatory mechanisms for HTA
topic selection. An overall aim of this study was to describe
quantitatively and qualitatively progression and ﬁndings from
HTA topic selection process recently developed by HITAP.
METHODS: The process involved potential users of HTA infor-
mation namely 1) public health insurers; 2) national health policy
makers; and 3) HITAP public funding organizations. In Decem-
ber 2006, these key players were invited to submit the topics
needed to be assessed based on their considerations. The submit-
ted topics were reviewed and prioritised by HITAP researchers in
January 2007 using several preset criteria. Furthermore, a con-
sultation workshop was conducted and the representatives from
those organisations submitted the HTA topics provide justiﬁca-
tions and prioritize their own list of top ten HTA topics needed
to be assessed in 2007. Results from each organisation were
analysed and the ﬁnal list made by workshop participants were
compared with the list made by HITAP researchers. RESULTS:
Fifty-one topics were submitted from ten organisations.
However, only 29 distinct HTA topics were met inclusion criteria
and then included in the priority setting process. Most topics
were pharmaceuticals (51%), medical procedures (24%),
medical devices (15%) and health policy (10%). At ﬁnal, six out
of ten topics selected by HITAP researchers were the same as
those made by the representatives from public health authorities.
CONCLUSION: Findings from this study illustrated the possi-
bility to make HTA topic selection process to be systematic,
transparent and participatory, which would eventually increase
the usefulness and credibility of HTA.
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OBJECTIVES: Between 1994–2006 the budget for pharmaceu-
tical reimbursement of the Hungarian National Health Insurance
Fund Administration (OEP), the only health care ﬁnancing
agency in Hungary, showed signiﬁcant deﬁcit. It means that the
actual drug expenditures became much higher at the end of the
year as it was originally planned at the beginning of the ﬁscal
year. The aim of the study to analyse the drug budget of the OEP
by identifying the pattern of this deﬁcit. METHODS: Data
derived from the ﬁnancial database of the Hungarian National
Health Insurance Fund Administration, covering the period
1994–2006. We analysed the planned and the actual drug budget
focusing on the deﬁcit. Deﬁcit was calculated as follows: dividing
the gap between the planned and the actual budget by the actual
budget. RESULTS: In each year between 1994–2006 we found a
deﬁcit at the drug budget of the OEP. This deﬁcit varied between
2.8% (lowest, 1996) and 36.6% (highest, 2006) of total actual
expenditures. We found 4 peaks on the diagram showing the
deﬁcit in the following years: 1994 (21.5%), 1998 (32.1%),
2002 (36.6%) and 2006 (30.4%). In each of these years, both
national governmental and local elections were held in Hungary.
CONCLUSION: We found deﬁcit in the drug budget of the
Hungarian OEP in each year between 1994–2006, however the
highest deﬁcit occurred in those years with political elections.
Such strong coincidence between political elections and drug
budget should be omitted as soon as possible in order to provide
a more transparent way of drug reimbursement policy.
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OBJECTIVES: To compare Canadian brand and generic drug
prices and U.S. generic drug prices for ten months following U.S.
brand patent expiration and to bring attention to a growing
source of competition during a generic company’s 180-day mar-
keting exclusivity period. METHODS: The Canada/U.S. Internet
Pharmacy Drug Price Database contains weekly prices since
January 2005 of more than 50 prescription medications from
eight Canadian and ﬁve U.S. on-line pharmacies. Ten months of
pricing data ($US) were extracted and compared for the Cana-
dian and U.S. brand and generic versions of sertraline and sim-
vastatin following U.S. patent expiration in 2006. RESULTS:
During the ﬁrst six months after U.S. patent expiration, the
average prices of brand and generic sertraline 100 mg from
Canadian on-line pharmacies were 11.4 and 45.5 percent less,
respectively, than the price of generic sertraline from U.S. on-line
pharmacies. Canadian brand and generic simvastatin 20 mg were
32.2 and 60.4% less expensive, respectively, than U.S. generic
simvastatin. At the tenth month post U.S. patent expiration, the
average price of the Canadian brand product exceeded that of the
U.S. generic product for both sertraline (by 15.8%) and simvas-
tatin (by 35.2%). However, Canadian generic products were still
less expensive than U.S. generic products (sertraline, 34.3% less;
simvastatin, 41.6% less). Prices for U.S. generic sertraline and
simvastatin dropped an average of ﬁve and 14 percent monthly,
respectively, after the exclusivity period. CONCLUSION: U.S.
generic drugs can be more expensive than both brand and generic
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products from Canadian on-line pharmacies during a 180-day
exclusivity period. A decrease of U.S. generic prices is expected
following this period as more products enter the market, and U.S.
prices over time typically fall below those of Canadian generic
prices. The availability of Canadian drugs to U.S. residents
increases the short-run competition to independent and autho-
rized generic companies during exclusivity periods.
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OBJECTIVES: Patent protection is the key condition of phar-
maceutical innovation. After patent expiry utilisation of generic
drugs decreases health care expenditure, and alleviates the scar-
city of health care budget. Our objective was to measure the
ability of generics to reduce the pharmaceutical expenditure in
the Hungarian market. METHODS: Drug utilisation records of
10 substances with patent expiry between 2001–2006 have
been compared 12 months before and after the entry of the ﬁrst
generic product. RESULTS: Although entry of generics reduced
daily therapeutic costs, the increase in volume sales outbal-
anced the potential savings in drug budget. Overall generic
drugs increased the expenditure of a subtance with no patent
protection by 30.1%, the public reimbursement by 25.7%, and
unit sales by 21.0%. In 5 cases the originator successfully con-
verted the majority of patients to a non-substitutable formula-
tion. When we limited our analysis to substances with no
restrictions in generic substitution, public reimbursement and
unit sales were still increased by 21.1%, 17.4% and 18.6%
respectively. CONCLUSION: The entry of generic drugs in
Hungary—as opposed to the international experience—did not
reduce pharmaceutical expenditure between 2001–2006, what
is more, generics increased the tendency of pharmaceutical
spending. The main reason for this failure was the inappropri-
ate generic drug policy. The lack of delisting, the low generic
price erosion, the lack of incentives to physicians and phar-
macists to switch patients to generic products, the branded
promotional campaigns by generic manufacturers, and the con-
version of patients to patented formulations by original manu-
facturers contributed to the inefﬁciency of the generic
programme in Hungary.
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OBJECTIVES: Policymakers increasingly use a policy of “condi-
tional reimbursement” of pharmaceutical care in order to obtain
more control over drug prescriptions and increase patient, phy-
sician and payer compliance to drug use. Our objective was to
resolve which factors determine the efﬁcient functioning of con-
ditional reimbursement as a policy-tool. METHODS: Drawing
on 65 interviews and two focus-group sessions with representa-
tives of patients, physicians, pharmacists, health insurers, phar-
maceutical industry, and policymakers, we studied stakeholders’
perspectives on the general functioning of conditional reimburse-
ment as a policy tool, with particular attention being paid to ﬁve
drugs. The participants’ data was completed and validated by
way of document analysis. RESULTS: Effectiveness of condi-
tional reimbursement depends on how it has been implemented
and/or how stringently regulations are enforced. The data
revealed controversies concerning the policy-tool’s transparency,
legitimacy, feasibility and commitment on the part of the stake-
holders. These controversies most often were caused by a lack of
coordination and cooperation within the network of drug reim-
bursement. Yet, a good network in which coordination and coop-
eration are facilitated appeared a necessary, but sometimes not
sufﬁcient condition. Case-speciﬁc characteristics have the poten-
tial to make or break the networks in which the instrument is
embedded and often are beyond control of the policymakers.
CONCLUSION: Problems occur when the conditional reim-
bursement policy fails to connect to the range of diverse interests
of those carrying the instrument to its effect. Conditional reim-
bursement has the potential to work if a more or less stable
network, in which cooperation and coordination are organized,
is available or can be created. Moreover, policymakers should
take into account whether case-speciﬁc characteristics will ﬁt into
or frustrate the network. If both prerequisites are available/
positive the instrument will more likely be found to be legitimate
and transparent, and consequently the compliance by its users
will rise.
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OBJECTIVES: The introduction of generic price-regulated
systems in many European countries, the trend towards interna-
tional generic medicine companies, and competition from Indian
companies emphasise the need to gain insight into international
prices of generic medicines. The aim of this study is to compare
generic medicine prices in ambulatory care in Belgium with prices
in other countries in 2005. The price difference between original
and generic medicines in Belgium is also elicited. METHODS:
Data on ex-manufacturer prices of generic medicines of 15
molecules/strengths were derived from IMS Health. Belgian
prices were compared with prices observed in Denmark, France,
Germany, India, The Netherlands, Norway, Spain, Sweden and
the UK. Comparability of pharmaceutical form was attained by
limiting the analysis to medicines in immediate-release, oral,
solid dosage forms. For each molecule/strength, the average price
per standard unit weighted by volume of sales of all available
package sizes and generic manufacturers was calculated.
RESULTS: India and Scandinavian countries had the lowest
ex-manufacturer prices of generic medicines of selected
molecules/strengths. The 15 molecules/strengths were, on
average, 63% cheaper in India than in Belgium. The average
price across generic molecules/strengths in Belgium (0.206 €) was
higher than the mean price across all countries (0.190 €). The
highest average price levels were observed in France (0.254 €),
The Netherlands (0.260 €) and Germany (0.269 €). Ex-
manufacturer prices of a speciﬁc generic molecule/strength varied
between countries by a factor 3–36, depending on the molecule/
strength. The price difference between original and generic
medicines generally ranged from -12% for simvastatin 20 mg
to -62% for enalapril 5 mg in Belgium. CONCLUSION:
Ex-manufacturer prices of selected generic medicines varied sub-
stantially between countries. India has emerged as a low-cost
producer of generic medicines. The international price compari-
son reveals that there may be scope for reducing generic medicine
prices in a number of countries.
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